Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

NCT00879086 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00879086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00879086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2009
Completion date
April 30, 2014
Enrollment
104 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer